Four new phenolic glycosides,including two flavonoid glycosides(1 and 2) and two lignan glycosides(3 and 4),were isolated from the traditional Chinese medicine formula,Baoyuan decoction.Their structures were establish...Four new phenolic glycosides,including two flavonoid glycosides(1 and 2) and two lignan glycosides(3 and 4),were isolated from the traditional Chinese medicine formula,Baoyuan decoction.Their structures were established by detailed analysis of the NMR and HR-ESI-MS spectroscopic data and their absolute configurations were determined by the experimental electronic circular dichroism data as well as chemical methods.Furthermore,the sources of the four new compounds were determined by the UPLC-Qtrap-MS method,which proved that 1 and 2 are originated from Glycyrrhiza uralensis,and 3 and4 are from Cinnamomum cassia.展开更多
Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the tr...Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the treated group used BYQS combined with Lotensin and the control group administered with essential amino acid combined with Lotensin. Changes of renal functions and tubular labelled proteins were observed. Results: The markedly effective rate and total effective rate of the treated group were 63.3% and 93.3% respectively, and those of the control group were 30.0% and 56.7% respectively, the effect of the treated group was obviously better than that of the control group ( P <0.01). In the treated group after medication, blood urea nitrogen, serum creatinine and clearance rate of creatinine were improved significantly ( P <0.01), while Tamm Horfau protein increased significantly ( P <0.01). Conclusion: BYQS could alleviate tubular interstitial injury significantly so as to improve the renal function and enhance the effective rate in treating CRF.展开更多
Chronic renal failure patients (as test group) under treatment by Baoyuan Dahuang De-coction, other 20 cases (as control group) by western medicine, mainly coated aldehyde oxystain, hadcommonly blood urea nitrogen and...Chronic renal failure patients (as test group) under treatment by Baoyuan Dahuang De-coction, other 20 cases (as control group) by western medicine, mainly coated aldehyde oxystain, hadcommonly blood urea nitrogen and creatinine decreased. But among the test group, the hemoglobin in-creased obviously, the symptons of fatigue, lassitude in loin and legs, lack of appetite, sexual disorder,and mental depression improved markedly (P<0. 01) . and estradiol, progesterone, testosterone as wellas creatine phosphokinase were regulated notably compared with before treatment (P<0.01) . Whereasin the control group, the symptoms were not significantly improved, hemoglobin, levels of sex hormonesand creatine phosphokinase differed slightly. It is concluded that Baoyuan Dahuang Decoction possessesefficacy to improve chronic renal failure patients' vitality and ability, the mechanism of which is related toanemia rectification and membrane function.展开更多
Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hem...Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hemodialysis in patients of terminal stage of renal disease (TSRD). Methods : Twenty cases of TSRD were treated with BYQS combined with hemodialysis once every 5 days and the effect was observed and compared with control group treated with routine hemodialysis once every 3 days. Results : The increasing levels of serum creatinine, and blood urea nitrogen of BYQS group at dialysis interval were all lower than those of the control group (P< 0. 01 ). After 3 months' treatment, serum creatinine, blood urea nitrogen of BYQS group were lower than those before treatment, plasma albumin, lipoprotein, urine level of prostaglandin and anemia were all improved to various extent, but the creatinine clearance rate was unchanged. Conclusions : BYQS could prolong the interval and reduce the times of dialysis by way of regulating the lipid metabolic disorder, improving pathological change of kidney and protecting function of residual kidney unit. BYQS combined with hemodialysis is a good way of integrated traditional Chinese and Western medicine in treating TSRD.展开更多
目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊...目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊顺序编号,采用随机数字表法将其分为对照组和观察组,每组各50例。对照组采用无创正压通气治疗,观察组在对照组基础上增加人参补肺汤合保元汤。治疗12周后,观察比较两组患者治疗后临床疗效,比较两组患者治疗前后中医证候积分、肺功能指标[呼气峰值流速(Peak Expiratory Flow,PEF)、第一秒用力呼气量(Forced Expiratory Volume in First Second,FEV1)、第一秒用力呼气量占用力肺活量比率(FEV1/FVC)]、慢性阻塞性肺疾病自我评估测试问卷(COPD Assessment Test,CAT)评分、改良版英国医学研究委员会呼吸问卷(Modified British Medical Research Council,mMRC)评分及无创正压通气时间,同时比较两组患者治疗前后血清基质金属蛋白酶-9(Matrix Metalloproteinase-9,MMP-9)、环氧化酶-2(Cycloxygenase-2,COX-2)及可溶性髓样细胞触发受体-1(Soluble Triggering Receptor Expresses on Myeloid Cells-1,sTREM-1)表达水平及不良反应发生情况。结果治疗后观察组总有效率98.00%(49/50)优于对照组84.00%(42/50),差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,而肺功能指标PEF、FEV1/FVC及FEV1较治疗前升高,差异有统计学意义(P<0.05);且观察组中医证候积分低于对照组,肺功能指标高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者CAT及mMRC评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组CAT及mMRC评分均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组机械通气时间(103.57±10.38)h低于对照组机械通气时间(119.48±11.47)h,差异有统计学意义(P<0.05)。治疗后两组患者MMP-9、COX-2及sTREM-1水平较治疗前降低,差异有统计学意义(P<0.05);且观察组MMP-9、COX-2及sTREM-1水平均低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论人参补肺汤合保元汤联合无创正压通气能提高COPD肺肾气阴两虚证患者的治疗效果,降低患者中医证候积分,改善肺功能,缩短患者机械通气时间,调节细胞因子水平,安全可靠。展开更多
基金financially supported by the National Natural Sciences Foundation of China(Nos.81222051 and 81530097)the National Key Technology R&D Program“New Drug Innovation”of China(No.2012ZX09301002-002-002)
文摘Four new phenolic glycosides,including two flavonoid glycosides(1 and 2) and two lignan glycosides(3 and 4),were isolated from the traditional Chinese medicine formula,Baoyuan decoction.Their structures were established by detailed analysis of the NMR and HR-ESI-MS spectroscopic data and their absolute configurations were determined by the experimental electronic circular dichroism data as well as chemical methods.Furthermore,the sources of the four new compounds were determined by the UPLC-Qtrap-MS method,which proved that 1 and 2 are originated from Glycyrrhiza uralensis,and 3 and4 are from Cinnamomum cassia.
文摘Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the treated group used BYQS combined with Lotensin and the control group administered with essential amino acid combined with Lotensin. Changes of renal functions and tubular labelled proteins were observed. Results: The markedly effective rate and total effective rate of the treated group were 63.3% and 93.3% respectively, and those of the control group were 30.0% and 56.7% respectively, the effect of the treated group was obviously better than that of the control group ( P <0.01). In the treated group after medication, blood urea nitrogen, serum creatinine and clearance rate of creatinine were improved significantly ( P <0.01), while Tamm Horfau protein increased significantly ( P <0.01). Conclusion: BYQS could alleviate tubular interstitial injury significantly so as to improve the renal function and enhance the effective rate in treating CRF.
文摘Chronic renal failure patients (as test group) under treatment by Baoyuan Dahuang De-coction, other 20 cases (as control group) by western medicine, mainly coated aldehyde oxystain, hadcommonly blood urea nitrogen and creatinine decreased. But among the test group, the hemoglobin in-creased obviously, the symptons of fatigue, lassitude in loin and legs, lack of appetite, sexual disorder,and mental depression improved markedly (P<0. 01) . and estradiol, progesterone, testosterone as wellas creatine phosphokinase were regulated notably compared with before treatment (P<0.01) . Whereasin the control group, the symptoms were not significantly improved, hemoglobin, levels of sex hormonesand creatine phosphokinase differed slightly. It is concluded that Baoyuan Dahuang Decoction possessesefficacy to improve chronic renal failure patients' vitality and ability, the mechanism of which is related toanemia rectification and membrane function.
文摘Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hemodialysis in patients of terminal stage of renal disease (TSRD). Methods : Twenty cases of TSRD were treated with BYQS combined with hemodialysis once every 5 days and the effect was observed and compared with control group treated with routine hemodialysis once every 3 days. Results : The increasing levels of serum creatinine, and blood urea nitrogen of BYQS group at dialysis interval were all lower than those of the control group (P< 0. 01 ). After 3 months' treatment, serum creatinine, blood urea nitrogen of BYQS group were lower than those before treatment, plasma albumin, lipoprotein, urine level of prostaglandin and anemia were all improved to various extent, but the creatinine clearance rate was unchanged. Conclusions : BYQS could prolong the interval and reduce the times of dialysis by way of regulating the lipid metabolic disorder, improving pathological change of kidney and protecting function of residual kidney unit. BYQS combined with hemodialysis is a good way of integrated traditional Chinese and Western medicine in treating TSRD.
文摘目的探讨人参补肺汤合保元汤联合无创正压通气治疗慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Diseases,COPD)肺肾气阴两虚证的临床疗效。方法选取2019年1月—2021年1月期间河南省周口市中医院收治的COPD患者100例,根据患者就诊顺序编号,采用随机数字表法将其分为对照组和观察组,每组各50例。对照组采用无创正压通气治疗,观察组在对照组基础上增加人参补肺汤合保元汤。治疗12周后,观察比较两组患者治疗后临床疗效,比较两组患者治疗前后中医证候积分、肺功能指标[呼气峰值流速(Peak Expiratory Flow,PEF)、第一秒用力呼气量(Forced Expiratory Volume in First Second,FEV1)、第一秒用力呼气量占用力肺活量比率(FEV1/FVC)]、慢性阻塞性肺疾病自我评估测试问卷(COPD Assessment Test,CAT)评分、改良版英国医学研究委员会呼吸问卷(Modified British Medical Research Council,mMRC)评分及无创正压通气时间,同时比较两组患者治疗前后血清基质金属蛋白酶-9(Matrix Metalloproteinase-9,MMP-9)、环氧化酶-2(Cycloxygenase-2,COX-2)及可溶性髓样细胞触发受体-1(Soluble Triggering Receptor Expresses on Myeloid Cells-1,sTREM-1)表达水平及不良反应发生情况。结果治疗后观察组总有效率98.00%(49/50)优于对照组84.00%(42/50),差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,而肺功能指标PEF、FEV1/FVC及FEV1较治疗前升高,差异有统计学意义(P<0.05);且观察组中医证候积分低于对照组,肺功能指标高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者CAT及mMRC评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组CAT及mMRC评分均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组机械通气时间(103.57±10.38)h低于对照组机械通气时间(119.48±11.47)h,差异有统计学意义(P<0.05)。治疗后两组患者MMP-9、COX-2及sTREM-1水平较治疗前降低,差异有统计学意义(P<0.05);且观察组MMP-9、COX-2及sTREM-1水平均低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论人参补肺汤合保元汤联合无创正压通气能提高COPD肺肾气阴两虚证患者的治疗效果,降低患者中医证候积分,改善肺功能,缩短患者机械通气时间,调节细胞因子水平,安全可靠。
文摘目的探讨保元汤合桃红四物汤加减对气虚血瘀型冠心病介入术后残余病变心绞痛患者血脂代谢及生活质量的影响。方法选取2020年2月—2022年8月期间北京中医医院怀柔医院收治的冠心病经皮冠状动脉介入术(Percutaneous coronary intervention,PCI)术后残余病变心绞痛患者84例,按照随机数字表法分为对照组和研究组,每组各42例。对照组采取常规西医治疗,研究组在对照组基础上采取保元汤合桃红四物汤加减方。治疗8周后,观察比较两组患者临床疗效、不良心血管事件及不良反应发生率,治疗前后中医证候积分、心绞痛发作情况(发作持续时长、发作频率)、血脂代谢指标[低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、三酰甘油(Triacylglycerol,TG)、总胆固醇(Total cholesterol,TC)]水平、生活质量分值。结果治疗后研究组治疗总有效率95.24%(40/42)明显高于对照组80.95%(34/42),差异有统计学意义(P<0.05)。治疗后两组患者胸闷、胸痛及面色紫暗、神疲乏力、心悸气短分值均较治疗前降低,差异有统计学意义(P<0.05);且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者心绞痛发作持续时长较治疗前缩短、心绞痛发作频率较治疗前降低,差异有统计学意义(P<0.05);且研究组心绞痛发作持续时长短于对照组、心绞痛发作频率低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者LDL-C、TG、TC水平较治疗前降低,HDL-C水平较治疗前升高,差异有统计学意义(P<0.05);且研究组优于对照组,差异有统计学意义(P<0.05)。治疗后两组患者精神健康、社会职能、总体健康、生理职能、躯体疼痛、活力、生理机能、情感职能分值均较治疗前升高,差异有统计学意义(P<0.05);且研究组高于对照组,差异有统计学意义(P<0.05)。治疗期间,研究组不良反应发生率9.52%(4/42)与对照组4.76%(2/42)比较,差异无统计学意义(P>0.05);研究组不良心血管事件发生率4.76%(2/42)低于对照组19.05%(8/42),差异有统计学意义(P<0.05)。结论常规西医联合保元汤合桃红四物汤加减治疗气虚血瘀型冠心病PCI术后残余病变心绞痛患者,可抑制心绞痛发作,缓解临床症状,调节血脂,利于提升疾病治疗效果,减少不良心血管事件的发生,改善患者生活质量,且具有安全性。
